WFH NETWORK

Considerations when Switching Patients from Established Standard Replacement Therapy to Extended Half-Life or Emerging Treatments?

 
Details

Year: 2018

Language: English

Author(s): John Pasi

View Online
Additional Information

In the Monday morning Medical Plenary, John Pasi gives an overview of the state of the art in clotting factor concentrates, describes currently available extended half-life products, and discusses health economics and choice rationale when switching.